SCHEMBL27186677

SCHEMBL27186677

COc1ccc(COc2nc(C)nc3c2cc(Br)c2[nH]ncc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 3/20 0.41
▸ CNR1 P21554 2/20 0.41
▸ PDE2A O00408 1/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.35
▸ MAOB P27338 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ PLK4 O00444 1/20 0.35
▸ CYP17A1 P05093 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GABRA1 P14867 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739066 0.80 CNR2 (0.42) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL27186566 0.77 PDE2A (0.41) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL29799700 0.77 PDE2A (0.41) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL27187150 0.75 HDAC1 (0.38) CNR2CNR1PDE2ANPSR1MAPT
SCHEMBL27186549 0.75 PDE2A (0.38) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL27186791 0.74 PDE2A (0.39) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL27187159 0.74 PDE2A (0.39) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL29799723 0.74 PDE2A (0.39) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL29799721 0.74 PDE2A (0.39) CNR2CNR1PDE2ANPSR1MAOB
SCHEMBL14616496 0.72 PDE2A (0.46) CNR2CNR1PDE2ANPSR1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
WO-2022187236-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109891-A1 NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 CNR2 3762/4885CNR1 2720/4885PDE2A 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback